Ispire Technology Inc. to Unveil Its Newest Technology Ispire ONE™ at Champs Trade Show 2023

unnamed (3) (1)

LOS ANGELES — Ispire Technology Inc. (“Ispire” or “the Company”) (NASDAQ: ISPR), a leader in vapor technology, providing high-quality, innovative products with first-class performance, announced today that it will unveil its most recent technology advancement for the cannabis industry, the Ispire ONE, at the Champs Trade Show, a premier business to business trade expo, in Las Vegas, on July 19 – 22, 2023. The show attracts a diverse range of industry professionals, including smoke and vape shops, dispensaries, glass blowers, online marketers, and cultivation product and service providers worldwide.

At the Champs Show, Ispire will introduce its proprietary and transformative Ispire ONE technology and products. Designed to

Advertisement

1.  eliminate capping issues in the manufacturing/co-packing process,

2.  increase consistency and quality of the filled devices,

3.  eliminate leaking, spitting, or overheating for cartridges, disposables, and PODs,

4.  improve consumer safety, as the devices are sealed in a sterilized factory environment to eliminate risk of contamination during filling process by Ispire’s customers,

Ispire ONE is intended to provide cannabis and CBD brands and copackers with significantly enhanced operating efficiency which could improve gross margin and elevate consumer safety.

Further details about the Ispire ONE technology can be found at the Ispire booth during the Champs Trade Show.

“We’re very proud to debut Ispire ONE at the Champs Trade Show. This pivotal advancement underscores our commitment to delivering top-tier products in the fast-growing CBD and cannabis vaping market. Designed with an unwavering focus on enhancing operational efficiency and product safety, we believe that this technology will provide a tangible competitive advantage for brands and manufacturers in these rapidly evolving sectors. As we continue to innovate, our commitment to delivering top-notch products at competitive pricing, and adding value for our shareholders remains steadfast,” said Michael Wang, CFO of Ispire.

About Ispire Technology Inc.

Ispire is engaged in the R&D, design, commercialization, sales, marketing and distribution of branded e-cigarettes and cannabis vaping products. The Company has or licenses from a related party more than 200 invention/design patents received or filed globally. Ispire’s tobacco products are marketed under the Aspire brand name and are sold worldwide (except in the PRC and Russia) primarily through our distribution network. Ispire’s cannabis products are marketed under the Ispire brand name primarily on an original design manufacturer (ODM) basis to other cannabis vapor companies. Ispire currently sells its cannabis vaping hardware only in the United States, and it recently commenced marketing activities in Canada and Europe, primarily in the European Union.

Please visit www.ispiretechnology.com and follow us on Facebook, Twitter, Instagram, Linkedin, Pinterest, and YouTube. Any information contained on, or that can be accessed through, the Company’s website, any other website or any social media, is not a part of this press release.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the safe harbor created by those sections. Forward-looking statements, which are based on certain assumptions and describe the company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the Company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements. Such forward-looking statements include, but are not limited to, risks and uncertainties including those regarding: the Company’s business strategies, the ability of the Company to market to the Ispire ONE, Ispire ONE’s success if meeting its goals, the ability of its customers to derive the anticipated benefits of the Ispire ONE and the success of their products on the markets; the Ispire ONE proving to be safe, and the risk and uncertainties described in “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Special Note Regarding Forward-Looking Statements” and the additional risk described in Ispire’s prospectus dated April 3, 2023 and in “Management’s Discussion of Financial Condition and Results of Operations” in the Company’s Form 10-Q quarterly report for the quarter and nine months ended March 31, 2023. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in the press release relate only to events or information as of the date on which the statements are made in the press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events except as required by law. You should read this press release with the understanding that our actual future results may be materially different from what we expect.

Advertisement
Previous articlePartnership Aims to Provide Relief to Coloradans with Physical Disabilities
Next articleSTORZ & BICKEL Announces Certification of Medical Vaporizers Under New EU Medical Device Regulations